Search

Displaying results 8861 - 8870 of 10000 in total
  1. Drug

    BZL101

    go.drugbank.com/drugs/DB05051
    Investigational

    BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.

  2. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential … This new insight suggests that the symptoms of bipolar disorder may be linked to dysregulation of energy metabolism of the brain.

  3. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is a new class of medicaction for treatment of cardiometabolic disease. … GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides

  4. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).

  5. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA<sub>A</sub> receptors. … Ganaxolone is the 3β-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids.

    Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Cytochrome P-450 Substrates
  6. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased af...

  7. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

  8. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.

    Categories: Venombin A
  9. Drug

    Prinomastat

    go.drugbank.com/drugs/DB05100
    Investigational

    As a lipophilic agent, prinomastat crosses the blood-brain barrier. … Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity.

  10. Drug

    Rupintrivir

    go.drugbank.com/drugs/DB05102
    Experimental

    Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. … Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.

    Categories: Heterocyclic Compounds, 1-Ring